Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Plexxikon, Inc.
Public Company Edition: Initial public offerings may take a holiday break, but 2020 already has been a remarkable year for IPOs in the US and China. Also, Arvinas led the latest follow-ons with a $400m offering followed by TG Therapeutics with a $275m stock sale.
Rare disease and cancer treatments are front and center in the latest batch of China new drug approvals, while a new biosimilar of a big seller moves into the spotlight.
The Phase III clinical trial showed a noticeable placebo effect compared with OV101.
Olema launched this year’s 75th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.